Table of Contents Purpose of This PDQ Summary Summary of Evidence
Significance Evidence of Benefit Get More Information From NCI Changes To This Summary (04/03/2008) Questions or Comments About This Summary More Information
Purpose of This PDQ Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about esophageal cancer prevention. This summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board.
Information about the following is included in this summary:
- Esophageal cancer incidence and mortality statistics and information about esophageal cancer risk factors.
- Interventions for esophageal cancer prevention.
- Benefits and harms of interventions to prevent esophageal cancer.
This summary is intended as a resource to inform clinicians and other health professionals about the currently available information on esophageal cancer prevention. The PDQ Screening and Prevention Editorial Board uses a formal evidence ranking system in reporting the evidence of benefit and potential harms associated with specific interventions. It does not provide formal guidelines or recommendations for making health care decisions. Information in this summary should not be used as a basis for reimbursement determinations.
This summary is also available in a patient version, which is written in less technical language.
Back to Top Summary of Evidence
Note: Separate PDQ summaries on Esophageal Cancer Screening, Esophageal
Cancer Treatment, and Levels of Evidence for Cancer Screening and Prevention Studies are also available.
Squamous Cell Carcinoma
Avoidance of tobacco and alcohol
Based on solid evidence, avoidance of tobacco and alcohol would decrease the risk of squamous cell cancer.[1]
The relative risk associated with tobacco use is 2.4, and the population
attributable risk is 54.2% (95% confidence interval [CI], 3.0–76.2).[1]
Retrospective cohort studies adjusted for tobacco use have shown a twofold to
sevenfold increase in risk of esophageal cancer in alcoholics compared with
rates for the general population.[2] Case-control studies have also suggested
a significantly increased risk of cancer of the esophagus associated with
alcohol abuse.
Description of the Evidence
-
Study Design: Evidence obtained from cohort or case-control studies.
-
Internal Validity: Fair.
-
Consistency: Multiple studies.
-
Magnitude of Effects on Health Outcomes: Large positive benefit.
-
External Validity: Fair.
Dietary factors
Based on fair evidence, diets high in cruciferous (cabbage, broccoli, cauliflower) and green and yellow vegetables and fruits are associated with a decreased risk of
esophageal cancer.[3,4]
Description of the Evidence
-
Study Design: Evidence obtained from cohort or case-control studies.
-
Internal Validity: Fair.
-
Consistency: Multiple studies.
-
Direction and Magnitude of Effect: Small positive.
-
External Validity: Fair.
Aspirin and nonsteroidal anti-inflammatory drug use
Based on fair evidence, epidemiologic studies have found that aspirin or nonsteroidal anti-inflammatory drug (NSAID) use is associated with decreased
risk of developing or dying from esophageal cancer (odds ratio [OR] = 0.57; 95% CI, 0.47–0.71).[5]
Description of the Evidence
-
Study Design: Evidence obtained from cohort or case-control studies.
-
Internal Validity: Fair.
-
Consistency: Good.
-
Magnitude of Effects on Health Outcomes: Large positive.
-
External Validity: Fair.
Based on solid evidence, harms of NSAID use include upper gastrointestinal bleeding and serious cardiovascular events such as myocardial infarction, heart failure, hemorrhagic stroke, and renal impairment.
Description of the Evidence
-
Study Design: Evidence obtained from randomized controlled trials.
-
Internal Validity: Good.
-
Consistency: Good.
-
Magnitude of Effects on Health Outcomes: Increased risk, small magnitude.
-
External Validity: Good.
Helicobacter pylori infection and gastric atrophy
Based on fair evidence, serum CagA antibodies and gastric atrophy are associated with an increased risk of esophageal squamous cell carcinoma (OR = 2.1; 95% CI, 1.1–4.0 and OR = 4.3; 95% CI, 1.9–9.6, respectively).[6]
Description of the Evidence
-
Study Design: Evidence obtained from cohort or case-control studies.
-
Internal Validity: Fair.
-
Consistency: Large study.
-
Magnitude of Effects on Health outcomes: Unknown magnitude.
-
External Validity: Fair.
Adenocarcinoma of the Esophagus
Gastroesophageal reflux/Barrett esophagus
Based on fair evidence, an association exists between gastroesophageal reflux disease (GERD) and
adenocarcinoma.[7,8] Long-standing GERD is associated with the development of
Barrett esophagus, a condition in which an abnormal intestinal type
epithelium replaces the stratified squamous epithelium that normally lines the
distal esophagus.
It is unknown whether elimination of gastroesophageal reflux by surgical or
medical means will reduce the risk of esophageal adenocarcinoma.[8,9]
Description of the Evidence
-
Study Design: Ecologic and descriptive studies.
-
Internal Validity: Fair.
-
Consistency: Good; multiple studies.
-
Magnitude of Effects on Health Outcomes: Unknown.
-
External Validity: Fair.
Aspirin and nonsteroidal anti-inflammatory drug use
Based on fair evidence, epidemiologic studies have found that aspirin or NSAID use is associated with decreased risk of developing or dying from esophageal cancer (OR = 0.57; 95% CI, 0.47–0.71).[5]
Description of the Evidence
-
Study Design: Evidence obtained from cohort or case-control studies.
-
Internal Validity: Fair.
-
Consistency: Good.
-
Magnitude of Effects on Health Outcomes: Positive; unknown magnitude.
-
External Validity: Fair.
Based on solid evidence, harms of NSAID use include upper gastrointestinal bleeding and serious cardiovascular events such as myocardial infarction, heart failure, hemorrhagic stroke, and renal impairment.
Description of the Evidence
-
Study Design: Evidence obtained from randomized controlled trials.
-
Internal Validity: Good.
-
Consistency: Good.
-
Magnitude of Effects on Health Outcomes: Increased risk, small magnitude.
-
External Validity: Good.
References
-
Siemiatycki J, Krewski D, Franco E, et al.: Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol 24 (3): 504-14, 1995.
[PUBMED Abstract]
-
Oesophagus. In: World Cancer Research Fund., American Institute for Cancer Research.: Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington, DC: The Institute, 1997, pp 118-129.
-
Chainani-Wu N: Diet and oral, pharyngeal, and esophageal cancer. Nutr Cancer 44 (2): 104-26, 2002.
[PUBMED Abstract]
-
Boeing H, Dietrich T, Hoffmann K, et al.: Intake of fruits and vegetables and risk of cancer of the upper aero-digestive tract: the prospective EPIC-study. Cancer Causes Control 17 (7): 957-69, 2006.
[PUBMED Abstract]
-
Corley DA, Kerlikowske K, Verma R, et al.: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124 (1): 47-56, 2003.
[PUBMED Abstract]
-
Ye W, Held M, Lagergren J, et al.: Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 96 (5): 388-96, 2004.
[PUBMED Abstract]
-
Lagergren J, Bergström R, Lindgren A, et al.: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (11): 825-31, 1999.
[PUBMED Abstract]
-
Fitzgerald RC: Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 55 (12): 1810-20, 2006.
[PUBMED Abstract]
-
Spechler SJ, Goyal RK: The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 110 (2): 614-21, 1996.
[PUBMED Abstract]
Back to Top Significance
Incidence and Mortality
Annually, it is estimated that 16,470 Americans will be diagnosed with esophageal
cancer and 14,280 will die of this malignancy. Of the new cases, it is estimated that 12,970 will
occur in men and 3,500 will occur in women.[1]
Two histological types account for the majority of malignant esophageal
neoplasms: adenocarcinoma and squamous carcinoma. The epidemiology of
these types varies markedly. In the 1960s, squamous cell cancers comprised
over 90% of all esophageal tumors. The incidence of esophageal adenocarcinomas
has risen markedly over the past 2 decades, such that it is now more prevalent
than squamous cell cancer in the United States and Western Europe, with most
tumors located in the distal esophagus.[2]. Although the overall incidence of
squamous cell carcinoma of the esophagus is declining, this histologic type
remains six times more likely to occur in black males than in white males.[3]
Incidence rates generally increase with age in all racial/ethnic groups. In
black men, however, the incidence rate for those aged 55 to 69 years
is close to that of whites aged 70 years and older. In black women, aged
55 to 69 years, the incidence rate is slightly higher than that of white women
aged 70 years and older.
Risk Factors
While risk factors for squamous cell carcinoma of the esophagus have been
identified (such as tobacco use, alcoholism, malnutrition, and infection with human
papillomavirus),[4] the risk factors associated with esophageal adenocarcinoma
are less well defined. The most important epidemiological difference between
squamous cell cancer and adenocarcinoma, however, is the strong association
between gastroesophageal reflux disease (GERD) and adenocarcinoma. The results
of a population-based case-controlled study suggest that symptomatic
gastroesophageal reflux is a risk factor for esophageal adenocarcinoma. The
frequency, severity, and duration of reflux symptoms were positively associated
with increased risk of esophageal adenocarcinoma.[5]
An interesting hypothesis relates the rise in the incidence of esophageal
adenocarcinoma to a declining prevalence of Helicobacter pylori infection in
Western countries. Reports have suggested that gastric infection with H.
pylori may protect the esophagus from GERD and its complications.[6] According
to this theory, H. pylori infections that cause pangastritis also cause a
decrease in gastric acid production that protects against GERD.[7] Patients
whose duodenal ulcers were treated successfully with antibiotics developed
reflux esophagitis twice as often as those in whom infection persisted.[8]
Other factors that have been suggested to explain the increased risk of
esophageal adenocarcinoma include obesity [9] and use of medications, such as
anticholinergics that can predispose to GERD by relaxing the lower esophageal
sphincter.[10]
GERD is a risk factor for esophageal adenocarcinoma because long-standing GERD
is associated with Barrett esophagus, the condition in which an abnormal
intestinal epithelium replaces the stratified squamous epithelium that normally
lines the distal esophagus.[11] The intestinal-type epithelium of Barrett
esophagus has a characteristic endoscopic appearance that differs from squamous
epithelium.[12] Dysplasia in Barrett epithelium represents a neoplastic
alteration of the columnar epithelium that may progress to invasive
adenocarcinoma.[13]
References
-
American Cancer Society.: Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society, 2008. Also available online. Last accessed October 1, 2008.
-
Holmes RS, Vaughan TL: Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 17 (1): 2-9, 2007.
[PUBMED Abstract]
-
Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (10): 2049-53, 1998.
[PUBMED Abstract]
-
Siemiatycki J, Krewski D, Franco E, et al.: Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol 24 (3): 504-14, 1995.
[PUBMED Abstract]
-
Lagergren J, Bergström R, Lindgren A, et al.: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (11): 825-31, 1999.
[PUBMED Abstract]
-
O'Connor HJ: Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. Aliment Pharmacol Ther 13 (2): 117-27, 1999.
[PUBMED Abstract]
-
Graham DY, Yamaoka Y: H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 3 (3): 145-51, 1998.
[PUBMED Abstract]
-
Labenz J, Blum AL, Bayerdörffer E, et al.: Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112 (5): 1442-7, 1997.
[PUBMED Abstract]
-
Lagergren J: Controversies surrounding body mass, reflux, and risk of oesophageal adenocarcinoma. Lancet Oncol 7 (4): 347-9, 2006.
[PUBMED Abstract]
-
Lagergren J, Bergström R, Adami HO, et al.: Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 133 (3): 165-75, 2000.
[PUBMED Abstract]
-
Spechler SJ, Goyal RK: The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 110 (2): 614-21, 1996.
[PUBMED Abstract]
-
Van Dam J, Brugge WR: Endoscopy of the upper gastrointestinal tract. N Engl J Med 341 (23): 1738-48, 1999.
[PUBMED Abstract]
-
Reid BJ, Blount PL, Rabinovitch PS: Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 13 (2): 369-97, 2003.
[PUBMED Abstract]
Back to Top Evidence of Benefit
Tobacco, Alcohol, and Dietary Factors
In the United States, squamous cell carcinoma of the esophagus is strongly
associated with tobacco and alcohol abuse. The risk declines with smoking
cessation. In China, esophageal cancer is associated with deficiencies of
nutrients such as retinol, riboflavin, alpha-carotene and beta carotene,
alpha-tocopherol, ascorbate, and zinc, and with exposure to specific
carcinogens (e.g., N-nitroso compounds).[1]
Chemoprevention
A prospective, placebo-controlled, esophagus chemoprevention study randomly assigned
610 high-risk Chinese subjects.[2] Subjects ranged in age from 35 to 64 years
and received either placebo or combined low-dose retinol (15 mg or 50,000 IU)
plus riboflavin (200 mg) and zinc gluconate (50 mg) for 13.5 months. Standard
histological evaluations (including two endoscopic biopsies) were made of 93% of
all entered subjects. Micronuclei from esophageal cells were obtained before
therapy began and after the 13.5 months of treatment. Serum levels of vitamin
A, beta carotene, riboflavin, and zinc were obtained at 0, 2, and 13.5 months.
The second report of this study presented micronuclei frequency results.[3] A
statistically significant reduction occurred in the mean percentage of
micronucleated esophageal cells in the active-treatment group compared with the
placebo group. The pattern of cell proliferation, another potential
intermediate endpoint marker, also improved.[4]
Two National Cancer Institute-sponsored phase III trials of combinations of multiple vitamins and
minerals have been reported. Both were conducted in a high-risk area of China
(Linxian). In one, a complex modified factorial design was used to study four
different vitamin/mineral combinations administered for 5 years at doses one to two
times the U.S. recommended daily
allowances (RDA) to 29,584 subjects.[5] The combination of beta carotene,
alpha-tocopherol, and selenium was associated with a nonstatistically
significant 4% reduction in the esophageal cancer mortality rate. The other
trial included only higher-risk subjects with esophageal dysplasia [6] and had
a two-arm design (26 vitamins and minerals, including beta carotene,
alpha-tocopherol, and selenium, at two to three times the U.S. RDA in one arm versus placebo in the other). This 6-year
intervention was associated with a nonsignificant change: a 16% reduction in
the esophageal cancer mortality rate. Similar studies have not been conducted
in the United States.
Aspirin and nonsteroidal anti-inflammatory drugs
A systematic review and meta-analysis of the association of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) with esophageal cancer identified two cohort and seven case-control studies published between 1980 and 2001.[7] Pooled results show a protective association between aspirin/NSAID use and esophageal cancer (odds ratio [OR] = 0.57; 95% confidence interval [CI], 0.47–0.71). Association with aspirin use was statistically significant (OR = 0.50; 95% CI, 0.38–0.66); association with NSAIDs was of borderline significance (OR = 0.75; 95% CI, 0.54–1.0). Aspirin/NSAID use was associated with lower risk of both adenocarcinoma (OR = 0.67; 95% CI, 0.51–0.87) and squamous cell carcinoma (OR = 0.58; 95% CI, 0.43–0.78).
References
-
Oesophagus. In: World Cancer Research Fund., American Institute for Cancer Research.: Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington, DC: The Institute, 1997, pp 118-129.
-
Muñoz N, Wahrendorf J, Bang LJ, et al.: No effect of riboflavine, retinol, and zinc on prevalence of precancerous lesions of oesophagus. Randomised double-blind intervention study in high-risk population of China. Lancet 2 (8447): 111-4, 1985.
[PUBMED Abstract]
-
Muñoz N, Hayashi M, Bang LJ, et al.: Effect of riboflavin, retinol, and zinc on micronuclei of buccal mucosa and of esophagus: a randomized double-blind intervention study in China. J Natl Cancer Inst 79 (4): 687-91, 1987.
[PUBMED Abstract]
-
Yang GC, Lipkin M, Yang K, et al.: Proliferation of esophageal epithelial cells among residents of Linxian, People's Republic of China. J Natl Cancer Inst 79 (6): 1241-6, 1987.
[PUBMED Abstract]
-
Blot WJ, Li JY, Taylor PR, et al.: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85 (18): 1483-92, 1993.
[PUBMED Abstract]
-
Li JY, Taylor PR, Li B, et al.: Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 85 (18): 1492-8, 1993.
[PUBMED Abstract]
-
Corley DA, Kerlikowske K, Verma R, et al.: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124 (1): 47-56, 2003.
[PUBMED Abstract]
Back to Top Get More Information From NCI
Call 1-800-4-CANCER
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 9:00 a.m. to 4:30 p.m. Deaf and hard-of-hearing callers with TTY equipment may call 1-800-332-8615. The call is free and a trained Cancer Information Specialist is available to answer your questions.
Chat online
The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 9:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
Write to us
For more information from the NCI, please write to this address:
- NCI Public Inquiries Office
- Suite 3036A
- 6116 Executive Boulevard, MSC8322
- Bethesda, MD 20892-8322
Search the NCI Web site
The NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use our “Best Bets” search box in the upper right hand corner of each Web page. The results that are most closely related to your search term will be listed as Best Bets at the top of the list of search results.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
Find Publications
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237), TTY at 1-800-332-8615.
Back to Top Changes To This Summary (04/03/2008)
The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available. This section describes the latest
changes made to this summary as of the date above.
Significance
Updated incidence and mortality estimates for 2008 (cited American Cancer Society as reference 1).
Back to Top Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site’s Contact Form. We can respond only to email messages written in English.
Back to Top More Information
About PDQ
Additional PDQ Summaries
Important:
This information is intended mainly for use by doctors and other health care professionals. If you have questions about this topic, you can ask your doctor, or call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
Back to Top |